logo
Site Network

Menu

Source Legend
  • Human-provided

    Entered or confirmed by an authorized person.

  • Google

    Imported Google information.

  • Trial-derived

    Calculated or extracted directly from associated trial records.

  • AI-inferred

    A capability inferred from trial history.

  • AI-extracted

    An explicit statement extracted from an official source.

  • Public registry

    Information from a public registry.

  • Site record

    Information held in the site record.

Source: Site record. Léon Bérard Center

+33478782828
institut.formation@centreleonberard.fr
Source: Site record.
https://www.centreleonberard.fr

Claim This Site

Are you the site administrator? Claim this site to update information.

Basic Information

Site Overview

Source: Human-provided.

The Centre Léon Bérard (CLB) is a leading private, non-profit comprehensive cancer center located at 28 Rue Laënnec in Lyon, France. As a prominent member of the national Unicancer network, the institution seamlessly integrates high-level patient care, cutting-edge scientific research, and medical education.

Business Status

Source: Human-provided. OPEN

Business Category

Source: Human-provided. Cancer treatment center

Business Subcategory

Source: Human-provided. Cancer treatment center
Source: Trial-derived.
740Total Trials
Source: Trial-derived.
158Recruiting Trials
Source: Trial-derived.
374Active Trials
Source: Trial-derived.
278Completed Trials
Source: Trial-derived.
907Unique Conditions
Source: Trial-derived.
431Unique Sponsors

Conditions

Source: Trial-derived. Breast Cancer (46)Source: Trial-derived. Cancer (24)Source: Trial-derived. Colorectal Cancer (20)Source: Trial-derived. Advanced Solid Tumor (19)Source: Trial-derived. Ovarian Cancer (17)Source: Trial-derived. Advanced Solid Tumors (15)Source: Trial-derived. Metastatic Breast Cancer (15)Source: Trial-derived. Prostate Cancer (15)

Sponsors

Source: Trial-derived. Centre Leon Berard (100)Source: Trial-derived. UNICANCER (66)Source: Trial-derived. Hoffmann-La Roche (61)Source: Trial-derived. Merck Sharp & Dohme LLC (52)Source: Trial-derived. Eli Lilly and Company (28)Source: Trial-derived. AstraZeneca (26)Source: Trial-derived. Daiichi Sankyo (24)Source: Trial-derived. AbbVie (23)

Research Technology

Research technology inferred from trial participation

Source: AI-inferred. Electronic data capture

Imaging & Diagnostics

Imaging and diagnostic capabilities inferred from trial participation

Source: AI-inferred. Electrocardiography (lead count not stated)
Source: AI-inferred. SPECT / nuclear medicine
Source: AI-inferred. CT Scan
Source: AI-inferred. 12-lead ECG
Source: AI-inferred. Echocardiography
Source: AI-inferred. PET-CT

Laboratory & Biospecimens

Laboratory and biospecimen capabilities inferred from trial participation

Source: AI-inferred. Clinical laboratory testing
Source: AI-inferred. Timed pharmacokinetic sampling and processing
Source: AI-inferred. Histology / pathology
Source: AI-inferred. Specimen packaging and shipment
Source: AI-inferred. Immunogenicity (anti-drug antibody) testing
Source: AI-inferred. Sequencing / genomics
Source: AI-inferred. Biobanking
Source: AI-inferred. Pharmacokinetic bioanalysis

Research Pharmacy & Investigational Product

Investigational-product capabilities inferred from trial participation

Source: AI-inferred. Hazardous / cytotoxic drug handling

Clinical Procedures

Clinical procedures inferred from trial participation

Source: AI-inferred. Intravenous infusion administration
Source: AI-inferred. Radiation therapy
Source: AI-inferred. Surgery / operating room
Source: AI-inferred. Tumour tissue biopsy (guidance not stated)

Accessibility & Parking

Accessibility Features

Source: Google. Wheelchair accessible entrance
Source: Google. Wheelchair accessible parking lot
Source: Google. Wheelchair accessible restroom

Amenities

Amenities Available

Source: Google. Restroom

Additional Capabilities

Other capabilities inferred from trial participation

Source: AI-inferred. Left ventricular ejection fraction assessment
Source: AI-inferred. Electronic patient-reported outcome (ePRO) diary system
Source: AI-inferred. Measurable residual disease (MRD) assessment
Source: AI-inferred. Minimal residual disease (MRD) testing
Source: AI-inferred. Tumour BRAF V600 mutation testing
Source: AI-inferred. Tumour EGFR mutation testing
Source: AI-inferred. Tumour response imaging
Source: AI-inferred. Tumour response imaging (modality not specified)